Where Will Moleculin Biotech Inc (MBRX) Stock Go Next After It Is Down 40.59% in a Week?

The market has been high on Moleculin Biotech Inc (MBRX) stock recently. MBRX gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Moleculin Biotech Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MBRX!

See Full MBRX Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With MBRX Stock Today?

Moleculin Biotech Inc (MBRX) stock is down -11.05% while the S&P 500 has gained 0.18% as of 1:54 PM on Tuesday, Mar 26. MBRX has fallen -$0.58 from the previous closing price of $5.25 on volume of 81,641 shares. Over the past year the S&P 500 has gained 31.43% while MBRX has fallen -67.68%. MBRX lost -$13.52 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Moleculin Biotech Inc click here.

More About Moleculin Biotech Inc

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. Click Here to get the full Stock Report for Moleculin Biotech Inc stock.